Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)

Clinical trial NCT00128102 · COMPLETED

Trial details

NCT number: NCT00128102
Sponsor: Merck Sharp & Dohme LLC
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Mesothelioma Lung Cancer

Start date: 2005-06-30
Primary completion: 2011-07-15
Enrollment: 661

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.